How to Safely Stop Repatha (Evolocumab)

How Evolocumab Works and Why That Matters for Stopping

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein the liver produces to break down LDL receptors on hepatocyte surfaces. By blocking PCSK9, evolocumab allows more LDL receptors to recycle back to the cell surface, pulling additional LDL-C particles out of the bloodstream. The result is a 50% to 60% reduction in LDL-C on top of statin therapy 1.

No Receptor Downregulation or Dependence

Unlike some hormonal therapies, evolocumab does not suppress endogenous receptor production through a feedback loop. Your liver continues manufacturing LDL receptors at its baseline rate while the drug is active. Once the antibody clears, PCSK9 resumes its normal degradation of LDL receptors, and receptor density returns to its pre-treatment state. There is no receptor downregulation to "recover" from.

Pharmacokinetic Clearance Timeline

Evolocumab has an effective half-life of approximately 11 to 17 days at steady state 2. After the final 140 mg biweekly dose, measurable drug concentrations persist for roughly 3 to 4 weeks. By week 8, PCSK9 activity has fully normalized and LDL receptor turnover returns to its untreated rate. This predictable clearance curve is what makes abrupt discontinuation pharmacologically safe, even if it is not always clinically wise.

What Happens to LDL Cholesterol After You Stop

LDL-C does not spike above baseline. It returns to it. A post-hoc analysis of the OSLER open-label extension studies showed that patients who discontinued evolocumab experienced LDL-C levels that returned to pre-treatment values within 4 to 12 weeks, with no overshoot phenomenon 3.

The Rebound Is Predictable, Not Dangerous Per Se

The word "rebound" can be misleading here. Evolocumab discontinuation does not cause LDL-C to swing higher than it was before treatment started. The clinical concern is not pharmacological rebound but rather the re-exposure to atherosclerotic risk. If a patient's untreated LDL-C is 180 mg/dL and evolocumab had been holding it at 45 mg/dL, stopping the drug means returning to 180 mg/dL. That level was already associated with plaque progression before treatment began.

Monitoring Schedule After Discontinuation

The 2018 AHA/ACC cholesterol guideline recommends repeat lipid testing 4 to 12 weeks after any lipid-therapy change 4. For evolocumab discontinuation specifically, a practical protocol looks like this:

• Week 4 post-last dose: fasting lipid panel to confirm trajectory
• Week 8 to 12: second lipid panel to establish new steady-state LDL-C
• If LDL-C exceeds threshold: discuss reinitiation, statin intensification, or ezetimibe addition

When Stopping May Be Appropriate

Not every patient who starts Repatha needs it indefinitely. Several clinical scenarios justify a structured discontinuation conversation.

Insurance or Cost Barriers

Evolocumab carries a list price of approximately $5,850 per year in the United States. Even after Amgen's 2023 price reduction, out-of-pocket costs vary widely by plan. A 2019 analysis in JAMA Cardiology found that PCSK9 inhibitor adherence at 12 months was only 29% in a real-world commercial claims database, with cost cited as the primary driver of discontinuation 5. If cost makes continued use impossible, a planned stop with lipid monitoring is safer than sporadic dosing.

LDL Target Achieved on Alternative Agents

Some patients initiated on evolocumab before maximizing statin plus ezetimibe therapy can reach guideline targets once those agents are fully optimized. The 2018 AHA/ACC guideline identifies an LDL-C threshold of <70 mg/dL for very high-risk ASCVD patients and <100 mg/dL for high-risk primary prevention 4. If high-intensity rosuvastatin (40 mg) plus ezetimibe (10 mg) achieves these numbers, evolocumab may be deprescribed.

Intolerable Side Effects

Injection-site reactions occur in approximately 5.7% of evolocumab-treated patients versus 4.2% on placebo, per the FOURIER trial data 1. Nasopharyngitis, upper respiratory infections, and myalgia have also been reported at rates marginally above placebo. These are generally mild, but for patients who find the injection burdensome, discontinuation is straightforward.

When Stopping Carries Significant Risk

Certain populations should not discontinue evolocumab without a compelling reason and a documented alternative LDL-lowering plan.

Established ASCVD with Recent Events

The FOURIER trial enrolled 27,564 patients with established ASCVD and followed them for a median of 2.2 years. Evolocumab reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) 1. Patients within 1 to 2 years of an acute coronary syndrome derived the largest absolute benefit. Stopping evolocumab in this window removes a measurable layer of protection.

Homozygous Familial Hypercholesterolemia

Patients with homozygous FH (HoFH) often have baseline LDL-C values exceeding 400 mg/dL and limited response to statins because of defective or absent LDL receptors. Evolocumab is FDA-approved for HoFH at 420 mg monthly 6, and discontinuation in this population typically leaves no pharmacologic path to adequate LDL-C control without lipoprotein apheresis.

Heterozygous FH Without Statin Tolerance

Statin-intolerant patients with heterozygous FH who rely on evolocumab as their primary LDL-lowering agent face a return to untreated LDL-C levels that may exceed 190 mg/dL. The 2022 European Atherosclerosis Society consensus statement notes that lifelong LDL-C exposure above 190 mg/dL is associated with a 10- to 20-fold increase in premature coronary artery disease 7.

Step-by-Step Discontinuation Protocol

This protocol applies to patients whose physician has confirmed discontinuation is clinically appropriate. It is not a self-directed guide.

Step 1: Confirm the Clinical Rationale

Document why the patient is stopping. Common documented reasons include cost, side effects, goal LDL-C achieved on other agents, or patient preference. The rationale should be recorded in the medical chart so future providers understand the decision context.

Step 2: Optimize Background Lipid Therapy First

Before the last evolocumab dose, confirm that background therapy is maximized:

• Statin: highest tolerated intensity (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg)
• Ezetimibe: 10 mg daily if not already prescribed
• Bempedoic acid: 180 mg daily for statin-intolerant patients (CLEAR Outcomes trial showed 13% MACE reduction) 8
• Inclisiran: consider as an alternative PCSK9-targeting agent if cost or injection frequency was the issue (dosed every 6 months after loading)

Step 3: Administer the Final Dose

There is no taper. Simply administer the last scheduled dose normally (140 mg SC every 2 weeks or 420 mg SC monthly).

Step 4: Schedule Post-Discontinuation Labs

• Fasting lipid panel at 4 weeks after the last injection
• Repeat fasting lipid panel at 8 to 12 weeks
• Lipoprotein(a) measurement if not previously documented (evolocumab reduces Lp(a) by approximately 25 to 30%, and this effect also reverses upon stopping) 9

Step 5: Reassess at 12 Weeks

Compare new steady-state LDL-C to the patient's risk-stratified target. If LDL-C exceeds the goal:

• Reintroduce evolocumab, or
• Switch to inclisiran (300 mg SC every 6 months), or
• Add bempedoic acid if not already prescribed, or
• Refer for lipoprotein apheresis in refractory FH

Evolocumab vs. Other PCSK9-Targeting Agents: Discontinuation Differences

Alirocumab (Praluent), the other FDA-approved PCSK9 monoclonal antibody, shares nearly identical discontinuation pharmacology. No taper is required, and LDL-C rebound follows the same 4 to 8 week timeline 10.

How Inclisiran Differs

Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 synthesis rather than binding circulating PCSK9 protein. Its effect persists longer after discontinuation because siRNA-mediated gene silencing in hepatocytes can last 3 to 6 months beyond the last dose. A patient switching from evolocumab to inclisiran does not need overlap dosing; beginning inclisiran at the time of the next scheduled evolocumab dose is sufficient 11.

Bempedoic Acid as a Bridge

For patients stopping evolocumab due to injection fatigue or cost, oral bempedoic acid (Nexletol, 180 mg daily) provides an additional 18% LDL-C reduction on top of statins. The CLEAR Outcomes trial (N=13,970) demonstrated a 13% reduction in MACE over 3.4 years in statin-intolerant patients 8. It does not replace the 50 to 60% LDL-C reduction of evolocumab, but it narrows the gap when combined with ezetimibe.

Common Misconceptions About Stopping Repatha

"Stopping Will Cause a Heart Attack"

Discontinuation does not trigger an acute cardiovascular event. The risk is cumulative re-exposure to elevated LDL-C over time, not an immediate pharmacologic withdrawal effect. A patient who stops for 8 weeks while resolving an insurance issue and then restarts is not at meaningfully increased short-term risk compared to someone who never interrupted therapy, though long-term data on intermittent dosing are limited.

"LDL Will Overshoot Past My Original Levels"

Post-hoc analyses from both OSLER and FOURIER extension data show no LDL-C overshoot 3. LDL returns to the expected value given the patient's background therapy, genetics, and diet. The fear of overshoot likely stems from confusion with statin discontinuation studies, where some observational data suggested transient inflammatory rebound, a phenomenon not observed with PCSK9 inhibitors.

"I Can Just Take It Every Other Month to Save Money"

Extended dosing intervals have not been validated in randomized trials for evolocumab. The FOURIER trial used 140 mg every 2 weeks or 420 mg monthly. Sub-therapeutic dosing could result in incomplete PCSK9 suppression and unpredictable LDL-C fluctuations. If cost is the primary concern, switching to inclisiran (2 injections per year after loading) or adding bempedoic acid as a replacement may be more evidence-based.

What Clinicians Should Document

The 2018 AHA/ACC guideline emphasizes shared decision-making in lipid therapy adjustments 4. When discontinuing evolocumab, the medical record should include:

• Pre-treatment and on-treatment LDL-C values
• Reason for discontinuation
• Background lipid-lowering regimen at time of discontinuation
• Target LDL-C and 10-year ASCVD risk score
• Follow-up lab schedule (4-week and 8- to 12-week lipid panels)
• Contingency plan if LDL-C exceeds target after drug clearance

The American College of Cardiology's 2022 Expert Consensus Decision Pathway on the role of nonstatin therapies recommends documenting the specific LDL-C level that would trigger reinitiation 12.

Patients who stop evolocumab should have their first follow-up lipid panel drawn no later than 4 weeks after the final injection, with a second panel at 8 to 12 weeks to confirm steady-state LDL-C on background therapy alone.